University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Evaluating 5-nitrofurans as trypanocidal agents.

Bot, C, Hall, BS, Alvarez, G, Di Maio, R, González, M, Cerecetto, H and Wilkinson, SR (2013) Evaluating 5-nitrofurans as trypanocidal agents. Antimicrob Agents Chemother.

Full text not available from this repository.


The nitroheterocycle nifurtimox, as part of a nifurtimox-eflornithine combination therapy, represents one of a limited number of treatments targeting Trypanosoma brucei, the causative agent of human African trypanosomiasis. The mode of action of this prodrug involves an initial activation reaction catalysed by a type I nitroreductase (NTR), an enzyme found predominantly in prokaryotes, leading to the formation of a cytotoxic unsaturated open chain nitrile metabolite. Here, we evaluate the trypanocidal activity of a library of other 5-nitrofurans against bloodstream form T. brucei as a preliminary step in the identification of additional nitroaromatic compounds that could potentially partner eflornithine. Biochemical screening against purified enzyme revealed that all 5-nitrofurans were effective substrates for TbNTR with the preferred compounds having apparent k(cat)/K(M) values approximately 50-fold greater than nifurtimox. For several compounds, in vitro reduction by this nitroreductase yielded products characterized by mass spectroscopy as either unsaturated or saturated open chain nitriles. When tested against bloodstream form T. brucei, many of the derivatives displayed significant growth inhibitory properties with the most potent compounds generating IC(50) values around 200 nM. The anti-parasitic activity of the most potent agents was demonstrated to be NTR dependent as parasites having reduced levels of the enzyme displayed resistance to the compounds while parasites over expressing TbNTR showed hypersensitivity. We conclude that other members of the 5-nitrofurans class of nitroheterocycles have potential to treat human African trypanosomiasis perhaps as an alternative partner prodrug to nifurtimox in the next generation of eflornithine-based combinational therapies.

Item Type: Article
Divisions : Surrey research (other units)
Authors :
Bot, C
Alvarez, G
Di Maio, R
González, M
Cerecetto, H
Wilkinson, SR
Date : 18 January 2013
DOI : 10.1128/AAC.02046-12
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 09:49
Last Modified : 24 Jan 2020 17:46

Actions (login required)

View Item View Item


Downloads per month over past year

Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800